Cryo-Cell International, Inc. Receives NYSE American Continued Listing Notice
Cryo-Cell International, Inc., a biotechnology company known for pioneering private cord blood banking, has received a notice from NYSE American LLC regarding its compliance with the exchange’s continued listing standards. The company disclosed that the exchange informed it that certain financial conditions have placed it out of compliance with specific requirements outlined in the NYSE American Company Guide.
The notification, referred to as a continued listing notice, was issued after the exchange reviewed the company’s financial results and determined that the firm no longer meets the criteria specified under Section 1003(a) of the NYSE American Company Guide. According to the notice, the issue stems from two key financial indicators reported by the company in its recent filings.
First, the exchange noted that the company reported a stockholders’ deficit as of November 30, 2025. A stockholders’ deficit occurs when a company’s total liabilities exceed its total assets, indicating negative equity on its balance sheet. This financial position can raise concerns among regulators and investors because it suggests the company may be facing financial pressure.
Second, the notice highlighted that the company posted net losses in two of its last three fiscal years. The relevant fiscal years cited by the exchange ended on November 30, 2023, November 30, 2024, and November 30, 2025. Under the listing rules of NYSE American, companies must meet certain financial performance thresholds, and repeated annual losses combined with negative equity can trigger compliance reviews.
Despite the notice, the exchange clarified that the company’s shares will continue to trade normally on the NYSE American market for the time being. The company’s common stock will remain listed under the ticker symbol “CCEL” while the firm works to address the compliance issue and present a strategy to restore its financial standing.
Importantly, the notice does not represent an immediate delisting action. Instead, it serves as a warning and initiates a process that allows the company an opportunity to regain compliance with the exchange’s requirements. During this period, the company is expected to develop and submit a formal plan outlining the steps it will take to correct the financial deficiencies cited by the exchange.
In accordance with NYSE American rules, the company must submit its compliance plan within the timeframe established by the exchange. This plan typically details financial restructuring strategies, operational improvements, or other measures designed to improve the company’s financial position and bring it back within the exchange’s required thresholds.
If the exchange reviews and accepts the plan, the company is generally granted up to 18 months from the date it received the notice to implement corrective actions and regain compliance. Throughout this remediation period, the company’s shares can continue to trade on the exchange, provided it adheres to the approved plan and continues to meet other applicable listing requirements.
During this timeframe, management may pursue various strategies to improve the company’s financial metrics. These could include cost reductions, operational restructuring, capital raising initiatives, debt restructuring, or other financial adjustments aimed at strengthening the company’s balance sheet and reducing losses. The effectiveness of these measures will play a key role in determining whether the company can successfully restore compliance.
However, the company cautioned that there is no guarantee that it will be able to achieve compliance within the permitted timeframe. Market conditions, operational performance, and financial results over the coming months could influence the outcome of the process.
Additionally, the exchange is not obligated to approve the company’s plan or grant extensions if progress toward compliance is deemed insufficient. If the company fails to regain compliance within the designated period, or if it does not meet other ongoing listing standards, the exchange could move forward with formal delisting procedures.
A delisting would mean that the company’s shares would no longer trade on the NYSE American exchange, which could potentially affect liquidity, investor confidence, and overall market visibility. Companies that face delisting sometimes move their shares to alternative trading platforms, though such markets typically offer lower visibility and trading volume compared to national exchanges.
About Cryo-Cell International, Inc.
Founded in 1989, Cryo-Cell International, Inc. is the world’s first private cord blood bank. More than 500,000 parents from 87 countries have entrusted Cryo-Cell International, Inc. with their baby’s cord blood and cord tissue stem cells. In addition to its private bank, Cryo-Cell International, Inc. has a public banking program in partnership with Duke University. Cryo-Cell’s public bank has provided cord blood for more than 700 transplants and operates a cord blood donation site at one of the country’s most prominent hospitals, Cedars–Sinai Hospital in Los Angeles. Cryo-Cell’s facility is FDA registered, cGMP-/cGTP-compliant and licensed in all states requiring licensure. Besides being AABB accredited as a cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. Cryo-Cell has the exclusive rights to PrepaCyte-CB, the industry’s most advanced cord blood processing technology.
Cryo-Cell’s mission is to provide premier cord blood and cord tissue cryopreservation services, to develop, manufacture and administer cellular therapies to significantly improve the lives of patients worldwide and to offer the highest quality and most cost effective biostorage solutions available.
Source Link :https://www.businesswire.com/
